Saffron Speciality Papers IPO

Incorporated in 2008, Saffron Speciality Papers Limited is engaged in the business of manufacturing and exporting Printed Paper Stationery and Back-to-School Paper Stationery. The company specializes in customized, mass-produced Back-to-School Paper Stationery and Printed Paper Stationery with diverse finishes, embellishments, and bindings. It also offers commercial printing services to corporations, banks, government agencies, trusts, and more. Products: Notebooks and Back-to-School Paper Stationery: They offers diverse notebooks and stationery, including EcoNama—eco-friendly notebooks made from recycled materials with biodegradable inks—launched in January 2025 for sustainability-conscious consumers. Commercial Printing: They launched this segment in April 2021 and began manufacturing in October 2022, offering high-margin commercial printing services for corporate clients with strict quality and customization needs. Paper Packaging Segment: They entered the Paper Packaging segment in 2024, starting limited-scale manufacturing with KBA & Heidelberg machines, targeting corporate clients in Electrical, E-commerce, and Food sectors. As of As of June, 30, 2025, the company had 142 permanent employees on the payroll and has employed 65 employees on a contract basis. Competitive Strengths: Experienced Management and operational team. Long-term Business relationship with customers. Exposure in export and domestic market segment. The location in Bhiwandi provides excellent connectivity via major highways (Mumbai-Nashik & Maharashtra Samruddhi Mahamarg- Mumbai to Nagpur), and proximity to the Nhava Sheva seaport is an added logistical advantage. Diversified Verticals, They are presently having Notebook / Back-to-School Paper Stationery & Commercial Printing segment. Thus, dependence on a single vertical for revenue generation is avoided.

Information on this page is for general awareness only and is not investment advice. Grey market premium (when shown) is unofficial and indicative. Always read the RHP/DRHP and consult a qualified adviser before investing.